Karyopharm Therapeutics
KPTI
103 hedge funds and large institutions have $306M invested in Karyopharm Therapeutics in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 30 reducing their positions, and 18 closing their positions.
463% more call options, than puts
Call options by funds: $4.58M | Put options by funds: $815K
30% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 30
2% more capital invested
Capital invested by funds: $300M → $306M (+$6.39M)
0.13% less ownership
Funds ownership: 84.2% → 84.07% (-0.13%)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
5% less funds holding
Funds holding: 108 → 103 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$16.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.9M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$3.45M |
| 4 |
AI
Atom Investors
Austin,
Texas
|
+$2.25M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$14.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.88M |
| 3 |
Renaissance Technologies
New York
|
-$4.52M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.41M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.92M |
KPTI Hedge Fund Activity: Q2 2019 in Review
103 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2019, worth a combined $306M — up 2.1% from $300M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of KPTI and 17 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 39 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $16.9M. The largest seller was Millennium Management, cutting an estimated $14.2M.
- 103 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2019, down from 108 in Q1 2019.
- Funds reported $306M of Karyopharm Therapeutics stock for Q2 2019, up 2.1% quarter-over-quarter.
- 17 funds opened new Karyopharm Therapeutics positions in Q2 2019 and 18 closed out, a net change of -1 holder.
- The largest Karyopharm Therapeutics buyer in Q2 2019 was OrbiMed, an estimated $16.9M added.
- The largest Karyopharm Therapeutics seller in Q2 2019 was Millennium Management, an estimated $14.2M sold.
Based on aggregated 13F filings for Q2 2019.